 Bridget Sanford
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 4 | 2020 | 169 | 0.590 |
Why?
| | Glioma | 4 | 2022 | 306 | 0.520 |
Why?
| | Brain Neoplasms | 3 | 2023 | 1022 | 0.350 |
Why?
| | Virus Activation | 2 | 2021 | 80 | 0.340 |
Why?
| | Virus Replication | 2 | 2021 | 405 | 0.290 |
Why?
| | Nuclear Proteins | 2 | 2021 | 597 | 0.260 |
Why?
| | DNA, Viral | 2 | 2017 | 356 | 0.260 |
Why?
| | Herpesvirus 3, Human | 2 | 2017 | 389 | 0.220 |
Why?
| | raf Kinases | 1 | 2021 | 12 | 0.210 |
Why?
| | Viral Proteins | 2 | 2021 | 296 | 0.210 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2022 | 61 | 0.200 |
Why?
| | Radiation | 1 | 2021 | 26 | 0.200 |
Why?
| | Cyclins | 1 | 2021 | 82 | 0.200 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2021 | 84 | 0.200 |
Why?
| | Antigens, Viral | 1 | 2021 | 181 | 0.190 |
Why?
| | Herpesviridae Infections | 1 | 2021 | 142 | 0.190 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 51 | 0.180 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 292 | 0.180 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 181 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 62 | 0.180 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 74 | 0.180 |
Why?
| | Infratentorial Neoplasms | 1 | 2019 | 50 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 187 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1167 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 200 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2022 | 736 | 0.160 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 20 | 0.160 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 82 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1597 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 65 | 0.150 |
Why?
| | Open Reading Frames | 1 | 2017 | 121 | 0.150 |
Why?
| | Sequence Deletion | 1 | 2017 | 171 | 0.150 |
Why?
| | Rhabdomyosarcoma | 1 | 2017 | 57 | 0.150 |
Why?
| | Genome, Viral | 1 | 2017 | 124 | 0.150 |
Why?
| | Immunophenotyping | 1 | 2017 | 278 | 0.140 |
Why?
| | Nerve Growth Factor | 1 | 2016 | 29 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.140 |
Why?
| | Neutrophils | 1 | 2022 | 1233 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2017 | 182 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 289 | 0.130 |
Why?
| | DNA Replication | 1 | 2016 | 211 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2022 | 2445 | 0.120 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 341 | 0.120 |
Why?
| | Virus Latency | 3 | 2021 | 84 | 0.120 |
Why?
| | NF-kappa B | 1 | 2017 | 670 | 0.120 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1059 | 0.100 |
Why?
| | Cell Proliferation | 4 | 2020 | 2275 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1974 | 0.100 |
Why?
| | Mice | 4 | 2022 | 15520 | 0.100 |
Why?
| | Aging | 1 | 2020 | 1670 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3730 | 0.090 |
Why?
| | Child | 7 | 2023 | 19129 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2022 | 2851 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 900 | 0.070 |
Why?
| | Humans | 13 | 2023 | 118974 | 0.060 |
Why?
| | Transcriptome | 2 | 2021 | 756 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 16 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2023 | 64 | 0.060 |
Why?
| | Cranial Irradiation | 1 | 2023 | 70 | 0.060 |
Why?
| | Adolescent | 4 | 2022 | 18480 | 0.050 |
Why?
| | Neopterin | 1 | 2022 | 8 | 0.050 |
Why?
| | Respiratory Burst | 1 | 2022 | 31 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 74 | 0.050 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 40 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 55 | 0.050 |
Why?
| | Gammaherpesvirinae | 1 | 2021 | 39 | 0.050 |
Why?
| | NADPH Oxidases | 1 | 2022 | 138 | 0.050 |
Why?
| | Apoptosis | 2 | 2022 | 2484 | 0.050 |
Why?
| | Superoxides | 1 | 2022 | 221 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 201 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 226 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 165 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 189 | 0.050 |
Why?
| | Young Adult | 3 | 2022 | 10793 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 258 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 167 | 0.050 |
Why?
| | Survivors | 1 | 2023 | 418 | 0.050 |
Why?
| | Epigenomics | 1 | 2020 | 107 | 0.050 |
Why?
| | Phagocytosis | 1 | 2022 | 364 | 0.050 |
Why?
| | Astrocytoma | 1 | 2020 | 113 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 90 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 576 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5116 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 333 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1032 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 445 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 248 | 0.040 |
Why?
| | Animals | 4 | 2022 | 33381 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 574 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 874 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2017 | 111 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2017 | 139 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2017 | 268 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 740 | 0.040 |
Why?
| | Virion | 1 | 2017 | 78 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 503 | 0.040 |
Why?
| | Oncogenes | 1 | 2017 | 111 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 922 | 0.040 |
Why?
| | Trigeminal Ganglion | 1 | 2016 | 22 | 0.040 |
Why?
| | Chromatin | 1 | 2020 | 441 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 158 | 0.040 |
Why?
| | Autopsy | 1 | 2016 | 89 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2016 | 67 | 0.040 |
Why?
| | Male | 5 | 2021 | 57801 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2017 | 193 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 348 | 0.030 |
Why?
| | Spleen | 1 | 2017 | 510 | 0.030 |
Why?
| | Histones | 1 | 2020 | 552 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1720 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 9491 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 356 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 228 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 755 | 0.030 |
Why?
| | Signal Transduction | 2 | 2017 | 4709 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 300 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3003 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 455 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 539 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1753 | 0.030 |
Why?
| | Adult | 3 | 2022 | 31512 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1158 | 0.030 |
Why?
| | Female | 4 | 2021 | 61565 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2017 | 770 | 0.030 |
Why?
| | Herpes Zoster | 1 | 2016 | 336 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2025 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4908 | 0.030 |
Why?
| | Cell Line | 1 | 2017 | 2707 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 811 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1774 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3457 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 27617 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4596 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.020 |
Why?
| | Aged | 1 | 2016 | 19657 | 0.010 |
Why?
|
|
Sanford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|